Core Insights - Johnson & Johnson (JNJ) is a leading player in the oncology segment, particularly in blood cancers and solid tumors, with its drug Darzalex being a foundational treatment [1][11] - JNJ's oncology sales are projected to reach $50 billion by 2030, supported by strong growth in existing products and new drug launches [4][11] Company Performance - JNJ's oncology segment accounts for approximately 27% of total revenues and 42% of its Innovative Medicine segment sales [2] - Oncology sales increased by 20.9% operationally in 2025, driven by Darzalex and Erleada, despite a decline in Imbruvica sales [2][11] - Darzalex generated over $14 billion in sales in 2025, marking a 22% year-over-year increase [1][11] - New cancer drugs Carvykti, Tecvayli, and Talvey contributed $3 billion in sales in 2025 [3][11] Future Outlook - JNJ is optimistic about its oncology pipeline, with expectations of continued momentum and new product launches [4][6] - The company has introduced innovative treatments like Inlexzoh and a subcutaneous formulation of Rybrevant plus Lazcluze, which are expected to enhance sales [5][6] Competitive Landscape - Other major players in the oncology market include Pfizer, AstraZeneca, Merck, and Bristol-Myers, each with significant oncology sales and robust pipelines [7][8][9][10][12] - JNJ's oncology sales growth outpaced competitors, with Pfizer's oncology revenues growing by 8% and AstraZeneca's by 14% in 2025 [8][9] Valuation and Market Performance - JNJ's stock has outperformed the industry, rising 51% over the past year compared to a 12.7% increase in the industry [13] - The company's shares are currently trading at a price/earnings ratio of 21.11, higher than the industry average of 18.69 [14]

ROMAINE: A BOUNCEBACK AND U.S. MANUFACTURING LEADS TO REBOUND IN U.S. EQUITIES. HERE AT BLOOMBERG HEADQUARTERS IN NEW YORK, I'M ROMAINE BOSTICK. KATIE: WE'RE KICKING YOU OFF TO THE CLOSING BELL HERE IN THE U.S., THE S&P 500 HEADING FOR RECORD HIGH.HIGHER BY ABOUT .5% RIGHT NOW. WE HAD U.S. ISM MANUFACTURING COME IN STRONG AS MORNING, YOU SEE THAT IN THE NASDAQ 100, GIVING A LIFT TO YIELDS. FOR KNOCKING ON THE DOOR OF 4.30%, THEN YOU LOOK AT THE DOLLAR, CONTINUING TO RALLY.BLOOMBERG DOLLAR SPOT INDEX HIGHER ...

Core Insights - Johnson & Johnson (J&J) has a strong R&D pipeline focused on immunology, oncology, and neuroscience, with significant advancements in 2025 [1][2][8] Pipeline and Product Approvals - J&J has achieved major clinical and regulatory milestones, including approvals for Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis [2][11] - Nipocalimab is being evaluated for various immune-mediated conditions and is considered to have pipeline-in-a-product potential [3] - Regulatory applications for icotrokinra, an oral treatment for moderate-to-severe plaque psoriasis, have been filed in the US and EU [4] - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $2.14 billion in sales in the first nine months of 2025 [5][11] Strategic Acquisitions and Expansions - The acquisition of Intra-Cellular Therapies added Caplyta, an antidepressant, to J&J's neuroscience portfolio [6] - J&J aims to expand the indications of currently marketed products, with recent approvals for Tremfya, Rybrevant, and Caplyta [7] Long-term Growth Potential - J&J's pipeline execution and recent product approvals position the company for sustained growth beyond short-term pressures, with multiple late-stage assets and significant sales potential across its Innovative Medicine portfolio [8] Competitive Landscape - J&J faces competition in the oncology space from major players like Pfizer, AstraZeneca, Merck, and Bristol-Myers, each with strong oncology portfolios and growth in sales [9][10][12][13][14] Financial Performance and Valuation - J&J's shares have outperformed the industry, rising 42.8% over the past year compared to a 17.5% increase for the industry [15] - The company's shares trade at a price/earnings ratio of 18.09, slightly above the industry average of 17.59 and its five-year mean of 15.65 [18] - The Zacks Consensus Estimate for 2025 earnings has increased from $10.86 to $10.87 per share, indicating positive earnings revisions [20]

>> WELCOME BACK. WE'RE HUNTING FOR YIELD WITH JENNY HARRINGTON. HER TOP DIVIDEND PLAYS FOR THE NEW YEAR.OKAY. YOU HAVE FOR FOR OUR VIEWERS. LET'S GO THROUGH THEM.>> OKAY I TRIED TO DO IT LIKE A CHRISTMAS PRESENT. SO I'M GIVING YOU A WIDE VARIETY, A REIT, A MATERIAL AND ENERGY AND A HEALTHCARE STOCK. WE'VE GOT AMCOR, BRISTOL-MYERS, ENBRIDGE AND VICHY.MOST OF THEM HAVE ABOUT A 6% YIELD OTHER THAN BRISTOL-MYERS, WHICH IS ABOUT 4.5%. THEY'RE ALL IN THAT KIND OF TEN TIMES EARNINGS RANGE. THEY ALL HAVE DECENT EAR ...

Correction: Bristol-Myers' chief medical officer is stepping down from his role after six years at the company https://t.co/zyU646R6Sg ...

Leadership Change - Bristol-Myers CEO is stepping down after six years [1] - The move is considered a surprise as the company seeks its next successful drug [1] Industry Focus - The pharmaceutical company is in a race to discover its next blockbuster drug [1]